Top AI in Cardiology Companies Transforming Cardiac Diagnosis, Monitoring, and Patient Care

The debut of AI in cardiology solutions in the healthcare industry has ushered a new era of data-driven diagnosis, bringing the power of technology for effective and early disease detection into limelight. Numerous health and research institutes have launched a range of studies aimed at assessing the reliability of AI-powered solutions for cardiac care. An instance is a study conducted by a research team at the Emory University, U.S., and published in the European Heart Journal in March 2026. The findings depicted that the AI analysis of mammograms can help predict the risk of fatal or serious heart disease. Another research undertaken by the Columbia University Irving Medical Center unveiled a new AI tool, EchoNext, which deploys ECGs for patient screening for numerous forms of structural heart disease. The model can detect signs of mitral regurgitation, heart failure, and severe aortic stenosis, among other findings.

Such studies are likely to pave the way to a host of opportunities for product development and enhanced care in the cardiac industry. The global market for AI in cardiology is poised to hit USD 14.22 billion by 2034 from a valuation of USD 2.78 billion in 2026, according to Fortune Business Insights. The market is set to depict a CAGR of 22.61% over 2026 to 2034.

AI in Cardiac Care: 5 Major Benefits at a Glance

Used for improving the diagnosis and treatment of cardiovascular diseases, AI in cardiology solutions are highly in demand in the areas of image interpretation, ECG analysis, surgical planning, and predictive analysis. The top 5 benefits of deploying these solutions comprise:

• Accurate Detection of Abnormalities
• Optimization of Treatment Plans
• Effective Data Management
• Enhanced ECG Interpretation
• Efficient Remote Monitoring

A Dive into the Industry Competition: What are the Key Steps Undertaken?

In line with the aforementioned benefits and the potential avenues for growth, eminent players are striving to create their mark by developing advanced solutions and seeking approval from regulatory bodies. They are also joining forces with other companies that align with their goals to bring enhanced and reliable solutions for patient care. A list of the top 10 AI in cardiology companies and the pivotal strategies that they are devising and deploying have been furnished below:

1. GE HealthCare Technologies Inc.

S.-based GE Healthcare Technologies depicts an interest in exploring AI solutions for patient treatment and care. The company’s Vscan Air SL along with the Caption Guidance software has been developed to secure diagnostic-quality echocardiographic images. In August 2025, the company showcased its latest cardiology innovations lineup at the ESC (European Society of Cardiology) Congress 2025. These CE-marked solutions comprise Revolution™ Vibe, CardIQ Suite™, and ViewPoint EchoPilot™. These offerings have been designed to enhance workflow efficiency and improve cardiac decision making.

2. Koninklijke Philips N.V.

With headquarters located in the Netherlands, Koninklijke Philips provides a range of solutions aimed at enhancing cardiac care. The AI in cardiology company’s EPIQ CVx allows for enhanced consistency, smart workflows, and innovation. In March 2026, Philips secured the 510(k) clearance from the U.S. FDA for its AI-powered cardiac MR planning solution, SmartHeart. The solution helps enhance the accessibility and consistency of cardiac MR by automating the planning process in a timeframe of less than 30 seconds.

3. Siemens Healthineers AG

Siemens Healthineers AG, based in Germany, has a range of cardiac care offerings on its portfolio and depicts a fervor to use AI-powered measurements for outcome enhancement. In addition to medical imaging, the AI in cardiology company also provides services in a range of areas, including point-of-care testing, laboratory diagnostics, and clinical specialties & diseases, among others. In November 2025, Siemens Healthineers unveiled Optiq AI, a new AI-powered imaging chain. The solution has been designed to enable precise image-guided procedures with the delivery of higher-quality low-dose images.

4. Canon Medical Systems Corporation

Canon Medical Systems Corporation has a range of diagnosis and treatment options for cardiovascular disorders. The Japan-based AI in cardiology player’s portfolio spans endovascular stent planning, cardiac functional analysis, and aorta analysis, among other areas. In December 2024, the company announced its expanded AI-powered solutions lineup for end-to-end workflow automation by introducing Vina Analytics, INSTINX AI-assisted user experience, and Remote Assist. These tools strengthen the company’s portfolio with protocol management, remote scan support, and automated processing of CT chest and neuro studies.

5. Medtronic plc

Medtronic is committed to deploying advanced technologies for enhancing the quality of healthcare solutions. The Ireland-headquartered company provides an array of products in the field of cardiac rhythm and diagnostics, with the AccuRhythm™ AI algorithms being a significant offering. In February 2026, the company shared plans for the acquisition of Cathworks, an Israel-based AI cardiology player, in a deal valued at USD 585 million.

6. iRhythm Technologies, Inc.

iRhythm Technologies, Inc., is committed to bringing new solutions in cardiac care through its FDA-approved AI technology. The AI in cardiology player, based in the U.S., offers advanced monitors that ensure uninterrupted and continuous data flow for enhanced patient care. In May 2025, the company joined forces with Lucem Health, a leading player in the AI-driven early disease detection space. The move aims at advancing the early detection of undiagnosed arrhythmias in patients with high risk.

7. Heartflow, Inc.

Heartflow, headquartered in the U.S., offers precision tools based on data-driven insights as well as AI-powered 3D modeling. The company is committed to introduce solutions for transforming the diagnosis and management of coronary artery disease. In November 2025, the company shared plans to release late-breaking insights underscoring Heartflow Plaque Analysis’ economic and clinical value. The data would be presented at the New Orleans-based AHA (American Heart Association) Scientific Sessions 2025.

8. Cleerly, Inc.

Cleerly, one of the top 10 AI in cardiology companies, has created a mark for introducing solutions aimed at preventing heart attacks. The AI-driven U.S.-based platform has been claimed to deliver clinically actionable insights by assessing plaque volume, stenosis severity, and other parameters for ensuring heart health. In January 2026, Aetna announced its coverage of the Cleerly® LABS plaque analysis for patients with known or suspected CAD (coronary artery disease). The solution supports the assessment and visualization of coronary arteries and quantifies artery stenosis and plaque by leveraging AI/ML technology.

9. Ultromics Ltd.

Based in the U.K., Ultromics is known for its AI-driven offerings that analyze routine echocardiograms for the diagnosis of complex cardiac disorders. The AI in cardiology player’s EchoGo® Heart Failure enables AI-powered HFpEF detection, supporting clinical decision-making. In July 2025, Ultromics raised a funding of USD 55 million in an L&G, Allegis Capital, and Lightrock-led Series C funding round. The move aims to enhance the scale of its heart failure diagnostic solutions.

10. Eko Health, Inc.

Eko Health is focused on bringing AI-powered solutions aimed at promoting the early diagnosis of cardiovascular diseases. The U.S.-based AI in cardiology company integrates the power of AI, software, and stethoscopes for disease detection. In November 2024, the company’s Sensora platform secured a new Category III CPT code from the AMA (American Medical Association). The platform features a group of FDA-cleared AI algorithms aimed at recognizing the signs of major cardiac conditions such as LVEF (low left ventricular ejection fraction), arrhythmias, and structural heart murmurs.

How will AI Reshape the Approach for Cardiac Diagnosis and Treatment?

The coming years are likely to witness a shift in the diagnosis rate of cardiac conditions with the increasing development and rollout of regulatory compliant AI-powered solutions. An instance is the May 2026 approval of the U.S. FDA for Coredio’s AI platform CPSE (Cardiac Performance Simulation Engine). Developed for reducing the rates of patient readmission, the platform provides hemodynamic assessments of heart failure patients on the basis of blood pressure cuffs and consumer-grade smartwatches. The development and approval of such technologies are anticipated to enhance care accessibility and reduce healthcare costs, with monitoring devices reducing the frequency of visits to hospital settings. Another significant advantage of using AI in cardiology solutions is the creation of personalized plans for treatment, which is likely to reshape the cardiac care landscape in the years to come.